New drug combo targets mysterious cancers
NCT ID NCT06754501
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining two immunotherapy drugs, atezolizumab and tiragolumab, can help control cancers of unknown primary (CUP) — cancers where doctors cannot find where the cancer started. Only 4 participants who have already tried chemotherapy are enrolled. The study focuses on safety and whether the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab and Tiragolumab (immune checkpoint inhibitors given by vein)
What this could lead to
If it works, this could point toward a new treatment option for people with cancer of unknown primary who have run out of standard options.
What could go wrong
This is a very small, early-phase trial with only 4 participants, so results may not apply widely. The drug combination may cause immune-related side effects and may not control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States